Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Clin Radiol. 2014 Feb;69(2):e100-7. doi: 10.1016/j.crad.2013.09.020. Epub 2013 Nov 28.
To study the clinical and multidetector computed tomography (MDCT) features of tumour-bowel fistula (TBF).
Fifty-one patients (27 women; mean age 57.4 years, range 30-77years) with TBF presenting to our institution between January 2005 and February 2012 were identified retrospectively from the radiology database. MDCT images before, at, and subsequent to diagnosis of TBF were reviewed by three radiologists in consensus; clinical presentation, management, and outcome were documented from electronic medical records.
Of 51 patients, small bowel (n = 22) was the most common site with gastrointestinal stromal tumour (GIST) being the most common sarcoma subtype (n = 10). TBF was treatment-associated (TTBF) in 40 patients [78%; 22 of whom had received molecular targeted therapy (MTT)], and spontaneous (STBF) in 11 patients (22%). Thirty-one patients (61%) were symptomatic at the time of TBF detection. TTBF was more often asymptomatic (19/40 versus 1/11; Fisher's exact test p = 0.03). In the TTBF group, 16 had a partial response, seven had stable disease, and 17 had progressive disease. Treatment was discontinued or changed to an alternative regimen in 27/40 patients, and 13/40 patients continued with the same regimen. TBF persisted in 27/33 patients (82%) who underwent CT follow-up. Thirty-one of the 51 patients were deceased at the time of analysis. Time from diagnosis of TBF to death was shorter with STBF (1.8 months) than with TTBF (6.4 months).
TBF is often associated with MTT and can be seen with treatment response or progression. TTBF is more frequently asymptomatic. TBF is usually managed conservatively by discontinuing treatment, but often persists on CT follow-up.
研究肿瘤-肠道瘘(TBF)的临床和多排螺旋 CT(MDCT)特征。
回顾性分析 2005 年 1 月至 2012 年 2 月期间在我院就诊的 51 例 TBF 患者(27 例女性;平均年龄 57.4 岁,范围 30-77 岁)的资料,从放射学数据库中检索出这些患者的 MDCT 图像,由 3 名放射科医生进行共识评估;从电子病历中记录患者的临床表现、治疗和转归。
51 例患者中,小肠(n=22)是最常见的部位,胃肠道间质瘤(GIST)是最常见的肉瘤亚型(n=10)。40 例患者为治疗相关性 TBF(TTBF)[其中 22 例接受了分子靶向治疗(MTT)],11 例为自发性 TBF(STBF)。31 例(61%)患者在 TBF 检测时出现症状。TTBF 更常无症状(19/40 例比 1/11 例;Fisher 确切检验,p=0.03)。在 TTBF 组中,16 例患者有部分缓解,7 例患者病情稳定,17 例患者病情进展。27/40 例患者停止或改变治疗方案,13/40 例患者继续使用原方案。33 例接受 CT 随访的患者中有 27 例(82%)TBF 持续存在。分析时 51 例患者中有 31 例死亡。STBF 患者从 TBF 诊断到死亡的时间(1.8 个月)短于 TTBF 患者(6.4 个月)。
TBF 常与 MTT 相关,可在治疗反应或进展时出现。TTBF 更常无症状。TBF 通常通过停止治疗进行保守治疗,但在 CT 随访中常持续存在。